KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update

KALA BIO, Inc. (NASDAQ:KALA) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 25,600 shares, an increase of 19.1% from the December 15th total of 21,500 shares. Based on an average daily trading volume, of 34,800 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.7% of the company’s stock are short sold.

Insider Activity at KALA BIO

In other news, major shareholder Bros. Advisors Lp Baker purchased 310,559 shares of the business’s stock in a transaction on Monday, December 30th. The shares were acquired at an average cost of $6.44 per share, with a total value of $1,999,999.96. Following the completion of the acquisition, the insider now owns 1,083,398 shares of the company’s stock, valued at $6,977,083.12. This trade represents a 40.18 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Mark T. Iwicki sold 5,779 shares of KALA BIO stock in a transaction on Monday, January 6th. The stock was sold at an average price of $7.63, for a total transaction of $44,093.77. Following the completion of the transaction, the chief executive officer now directly owns 280,076 shares in the company, valued at $2,136,979.88. This represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,506 shares of company stock valued at $72,531 over the last ninety days. 8.32% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP acquired a new position in KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for about 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th largest holding. SR One Capital Management LP owned about 15.76% of KALA BIO at the end of the most recent quarter. 24.61% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of KALA BIO in a report on Friday, November 15th.

KALA BIO Stock Performance

Shares of KALA traded up $0.24 during trading hours on Friday, reaching $7.25. 17,502 shares of the company traded hands, compared to its average volume of 39,220. The stock has a market capitalization of $33.42 million, a P/E ratio of -0.58 and a beta of -2.11. The company has a quick ratio of 2.15, a current ratio of 2.15 and a debt-to-equity ratio of 3.18. KALA BIO has a 12-month low of $4.21 and a 12-month high of $8.89. The business has a fifty day moving average price of $6.69 and a 200-day moving average price of $6.37.

KALA BIO (NASDAQ:KALA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50. Equities analysts anticipate that KALA BIO will post -10.84 EPS for the current fiscal year.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.